drugset / Trial / NCT06082934
Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 10 mg | Intravenous |
| Subject | Olverembatinib | Small molecule | 40 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | — |